Most Read Articles
Yesterday
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.

Ipratropium, salmeterol show therapeutic potential in multiple sclerosis

25 Sep 2019

Use of both ipratropium and salmeterol is associated with reduced likelihood of being diagnosed with multiple sclerosis (MS), according to a study, suggesting that the drugs may help prevent or stop the development of the disease in its early stages.

Researchers conducted a matched case–control study that examined the effect of exposure to ipratropium and salmeterol over the past 2 years between patients with MS (n=214) and matched general outpatients (control; n=2,164).

The mean age of the entire population was 41 years. Compared with controls, MS patients are more likely to be current smokers (34.6 percent vs 20.2 percent) and have a family history of MS (9.2 percent vs 0.5 percent) but had a lower prevalence of chronic pulmonary disease (0.9 percent vs 5.4 percent).

Prescriptions of ipratropium and salmeterol were consistently fewer in the MS vs control group in the past 1, 2 and 3 years before the index date. In multivariable Poisson regression model, prescriptions of either ipratropium or salmeterol in the past 2 years were higher by 3.2 (95 percent CI, 1.4–7.1; p=0.006) in the control group than in the MS group.

In the generalized structural equation model, use of ipratropium and salmeterol was strongly associated with reduced MS incidence (p=0.036), whereas smokers and individuals with family history of MS were more likely to be diagnosed with the disease (p<0.001).

The present data provide a platform for personalized medicine for high-risk populations of MS by tailoring treatments based on lifestyle and environmental factors, the researchers said. The next step in the research is to develop a randomized clinical trial evaluating ipratropium and salmeterol as a treatment option for patients with MS.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.